Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-

The Bitcoin Miner Turning Itself Into an AI Landlord
Core Scientific once made most of its money mining Bitcoin. Now long-term deals with CoreWeave and AMD are transforming its power-hungry sites into infrastructure for the AI boom.
-

Can a Cancer Drug Deliver Itself Straight to a Tumour? GSK Is Betting $110 Million on the Idea
HMPL-A830 links an EGFR-seeking antibody to a KRAS inhibitor. The design could concentrate a targeted drug inside cancer cells—but it has not yet shown safety or benefit in people.
-

When Is Nvidia’s GeForce RTX 6000 Series Coming? The Honest Answer
Nvidia has not announced its next generation of consumer graphics cards. An older leak points to late 2027, but later supply-chain reporting and a newer rumour make 2028 the more realistic expectation.
-

Google Is Betting That Hot Rock Can Power the AI Boom
Google has agreed to buy 396 megawatts from Fervo Energy’s enhanced-geothermal project in Utah. The deal could push an oilfield-inspired technology toward the energy mainstream—but the largest units are not operating yet.
-

Time Travel Is Real—But Only in One Direction So Far
Physics already lets clocks and people move into the future at unequal rates. Travelling backwards is far stranger: some equations permit it, but nature has supplied no wormholes, time loops or messages from tomorrow.
-

Can a Blood Test Tell Whether a Longevity Treatment Works? 51 Studies Put Biological-Age Clocks to the Test
Researchers compared 16 epigenetic clocks across 51 human intervention studies. Some detected consistent change, many interventions produced no clear signal, and a younger score still does not prove a longer life.
-

Can Galaxy Buds Work as Hearing Aids? Samsung’s FDA Clearance—and How It Compares With AirPods Pro
Samsung has received FDA clearance for software that turns selected Galaxy Buds into self-fitting over-the-counter hearing aids. Here is what the evidence shows, who can use it and how it differs from Apple’s approach.
-

The “Undruggable” Target Gives Way: FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA has approved the first broad RAS-targeted medicine for metastatic pancreatic cancer after a randomized Phase 3 trial showed substantially longer survival than standard chemotherapy. The result is important—but it applies to a defined group of patients and is not a cure.
-

NuScale vs Oklo: Two Very Different Routes to Small Nuclear Power
NuScale is pursuing a regulator-approved light-water module for multi-reactor plants. Oklo is developing smaller sodium-cooled powerhouses that it plans to own and operate. Here is what each company has actually achieved—and what remains unproven.
-

Can Anti-Gravity Ever Be Real? What Physics Actually Allows
Antimatter falls down, magnetic fields can levitate living tissue, and astronauts float while still under Earth’s pull. Here is where anti-gravity science ends and imitation begins.


